Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Magnetic Resonance Spectroscopy × Clear all

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03375307 2026-04-13

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Phase 2 Suspended

Urinary Bladder Neoplasms

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04936230 2025-08-17

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Phase 2 Terminated

1 enrolled 1 chart

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Phase 2 Completed

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03007719 2020-01-21

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Phase 2 Terminated

4 enrolled 8 charts

Urinary Bladder Neoplasms

NCT01821105 2016-03-02

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

Phase 2 Completed

21 enrolled 5 charts

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms